Chescapmanager’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Chescapmanager’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,672,379	Closed	-$3.03M	–	42
2023 Q2	$3.03M	Buy	1,672,379 +500	+0%	+$914	0.47%	34
2023 Q1	$2.21M	Buy	1,671,879 +1,162,492	+228%	+$1.9M	0.35%	38
2022 Q4	$861K	Buy	509,387 +147,671	+41%	+$187K	0.2%	31
2022 Q3	$669K	Hold	361,716	–	–	0.16%	38
2022 Q2	$1.11M	Sell	361,716 -224,310	-38%	-$1.37M	0.26%	37
2022 Q1	$4.23M	Sell	586,026 -385,088	-40%	-$3.79M	0.57%	37
2021 Q4	$15.9M	Buy	971,114 +621,948	+178%	+$7.24M	2.12%	18
2021 Q3	$3.47M	Sell	349,166 -138,534	-28%	-$1.38M	0.49%	45
2021 Q2	$4.88M	Hold	487,700	–	–	0.54%	44
2021 Q1	$4.86M	Buy	+487,700	New	+$5.04M	0.52%	49

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Chescapmanager's PRDS Position: Q3 2023 in Review

Chescapmanager sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 1,672,379 shares — an estimated $3.03M sold.

Chescapmanager first reported a position in PRDS in Q1 2021 and held it in 10 quarters. The position peaked at $15.9M in Q4 2021. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Chescapmanager reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Chescapmanager sold 1,672,379 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $3.03M.
Chescapmanager first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Chescapmanager's Pardes Biosciences, Inc. Common Stock position peaked at $15.9M in Q4 2021.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Chescapmanager's 13F filing for Q3 2023, filed 14 Nov 2023.